Evidence map›Paper›PMID 40739504›Full record

Observational studyCardiovascular diabetology2025

Diabetic kidney disease phenotypes and the risk of cardiovascular events: The Silesia Diabetes-Heart Project.

Oliwia Janota-Sosińska, Marta Mantovani, Krzysztof Irlik, Hanna Kwiendacz, Anna Olejarz, Patrycja Pabis, Aleksandra Włosowicz-Momot, Julia Piaśnik, Wiktoria Wójcik, Paulina Szromek-Białek and 4 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05626413 (Cardiovascular Disease and Diabetes in Silesian Patients), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05626413 unknown statusnot on this map

Cardiovascular Disease and Diabetes in Silesian Patients

Typeobservational_patient_registrySponsorMedical University of SilesiaRan2015 to 2026Enrolled4,000ConditionsDiabetes Mellitus
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Oliwia Janota-Sosińska *Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Marta Mantovani *Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
Krzysztof IrlikDepartment of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Doctoral School, Medical University of Silesia, Katowice, Poland.
Hanna KwiendaczDepartment of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. hkwiendacz@sum.edu.pl.
Anna OlejarzStudent's Scientific Association at the Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Patrycja PabisStudent's Scientific Association at the Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Aleksandra Włosowicz-MomotStudent's Scientific Association at the Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Julia PiaśnikStudent's Scientific Association at the Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Wiktoria WójcikStudent's Scientific Association at the Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Paulina Szromek-BiałekDepartment of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Uazman AlamLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
Janusz GumprechtDepartment of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Gregory Y H Lip *Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
Katarzyna Nabrdalik *Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.

Funding

Medical University of Silesia BNW-1-020/N/4/K
6 · The paper itself

Abstract

backgroundThe impact of diabetic kidney disease (DKD) phenotype on the cardiovascular (CV) risk remains ambiguous.

methodsThis was a prospective, single-center study (The Silesia Diabetes-Heart Project, NCT05626413) of people with diabetes mellitus (DM). The primary outcome was a composite of CV events during a median follow up of 2.8 years (IQR 1.7; 4.0). Individuals were divided into groups based on DKD phenotypes [reduced estimated glomerular filtration rate (eGFR) (< 60 mL/min/1.73 m

resultsAmong 2306 people with DM (mean age 58 ± 18 years, 51.9% males) those with DKD had higher CV events risk (aHR 1.02, 95% CI 1.01-1.03) compared to those without DKD. People with reduced eGFR (aHR 1.78, 95% CI 1.19-2.67) and those with reduced eGFR and elevated UACR (aHR 1.60, 95% CI 1.08-2.37) were at higher risk of CV events compared to people with normal eGFR and UACR, while people with elevated UACR only (aHR 0.91, 95% CI 0.62-1.32) did not had the risk heightened. Among people with DKD less frequent prescriptions with sodium-glucose co-transporter 2 inhibitors and renin-angiotensin-aldosterone system inhibitors were observed (OR 0.38, 95% CI 0.29-0.49, p < 0.001 and OR 0.39, 95% CI 0.30-0.50, p < 0.001, respectively) compared with the ones without DKD.

conclusionPeople with DKD, with reduced eGFR or both reduced eGFR and elevated UACR, but not with elevated UACR alone, are at higher CV risk. Personalizing therapy based on clinic-based renal phenotyping can facilitate the initiation of CV disease modifying therapy.

Indexed as

AlbuminuriaCardiovascular DiseasesDiabetic NephropathiesGlomerular Filtration RateKidneyAdultAgedBiomarkersFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPhenotypePolandPrognosisBiomarkersSodium-Glucose Transporter 2 InhibitorsCardiovascular-kidney-metabolic syndromeCardiovascular riskDiabetes mellitusDiabetic kidney diseaseDKD phenotypes

Identifiers

PMID40739504
PMCPMC12312546

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.